Skip to content

Prophylactic Vs Routine Replacement Therapy with Factor VIII In Hemophilia A Patients

A Comparative Study To Assess The Effect Of On Demand Vs Prophylactic Factor VIII Infusion On Annual Total Bleed Rate, Annual Joint Bleed Rate and Quality Of Life In Children Aged 12-18 Years With Severe Hemophilia A

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/02/049918
Enrollment
50
Registered
2023-02-21
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D66- Hereditary factor VIII deficiency

Interventions

Intervention1: Prophylactic factor VIII: Prophylactic factor VIII would be given thrice weekly in the dose of 15 IU per Kg per dose to the randomized prophylactic study arm for one year and the effect

Sponsors

Dr Sugandh Sareen
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Severe Hemophilia (Factor VIII levels 2. Age more than equal to 12 years to less than equal to 18 years at enrolment 3. more than equal to 6 treated joint bleeds in the previous one year 4. Inhibitor screen negavtive at enrolment 5. No evidence of hepatitis 6. Viral markers negative 7. Not on any prophylactic regimen in the last one year 8. Not on any non-factor replacement therapy

Exclusion criteria

Exclusion criteria: 1. Female Gender 2. Factor VIII levels >1% at diagnosis 3. Age 18 years at enrolment 4. 5. Inhibitor screen positive at enrolment 6. Evidence of hepatitis

Design outcomes

Primary

MeasureTime frame
Annual Total Bleed Rate, Annual joint Bleed rate and quality of lifeTimepoint: Baseline before the study initiation and after one year of study.

Secondary

MeasureTime frame
Hemophilia Joint Health Score, Incidence of inhibitors, Pettersson Joint score, IPSG MRI score, HEAD US scoring system, HAL/Ped-Hal, Functional Impairment Scoring for Hemophilia (FISH), Health Related Quality of lifeTimepoint: Inhibitor screening every 3 months Rest all parameters, at the start of the study protocol and end of one year.

Countries

India

Contacts

Public ContactSugandh Sareen

Guru Gobind Singh Medical College and Hospital

drvarunkaul2009@live.in9876569622

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026